Earlier this year, Phytopharm announced that their Phase II clinical trial of Cogane for the treatment of Parkinson’s diseases failed to show efficacy. In the light of these negative results, Phytopharm has announced that they are cutting staff and “looking to sell the business.” This announcement is disappointing not only for the Parkinson’s disease community, but also for the ALS community. In December 2012, Phytopharm announced their plans to develop Cogane for the treatment of ALS. Unfortunately, considering Phytopharm’s recent announcement, it is unlikely that Cogane will undergo further development for ALS.
Click here to read more.Share this: